Trial Profile
A triple crossover, driving study of Tasimelteon in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary) ; Zopiclone
- Indications Circadian rhythm sleep disorders
- Focus Adverse reactions
- 21 Sep 2018 New trial record
- 12 Sep 2018 Primary endpoint has not been met. (Meaningful and significant increase in Standard Deviation of Lateral Position (SDLP), a measure of lane weaving, compared to the placebo treatment), according to a Vanda Pharmaceuticals media release.
- 12 Sep 2018 Primary endpoint has been met. (Meaningful and significant increase in Standard Deviation of Lateral Position (SDLP), a measure of lane weaving, compared to the placebo treatment), according to a Vanda Pharmaceuticals media release.